spacer
home > ebr > summer 2016 > less is more
PUBLICATIONS
European Biopharmaceutical Review

Less is More

A recent Washington Post article ran with the title ‘Specialty drugs now cost more than median household income’. Medical costs are in the spotlight, and drug prices in particular garner the most attention. In a system where 80% of medical costs are affected by physician decisions, doctors are under increased pressure to balance patient needs against limited resources. The high price of speciality cancer drugs places the disparate interests of patient and payer into sharp focus.

New game-changing therapies seek to ‘cure’ certain serious or hereditary disorders, rather than treat them chronically. Gene therapy and cancer vaccines are a harbinger of the future. They are at once enormously expensive, and replace a lifetime of chronic care and dosing with a single curative regimen.

Success has considerable merit. Clearly, they promise to alleviate patient burden and suffering, while reducing medical resource utilisation. The missing links are business models and policy mechanisms to align the stakeholders on the high upfront cost of treatment, versus the long tail of future savings.

New therapies can be expensive. They entail the high production costs inherent in biologics. There are also technical barriers like immunogenicity, delivery system, specificity and duration. Payers and innovators together will need to resolve basic market issues: market size; clinical efficacy; comparative effectiveness; and overall budget impact. Even if it works, there are the regulatory issues: how long is the clinical trial? Should patients be enrolled by phenotype or genotype? What biomarker indicates a durable cure – and for how long should this be monitored?

The optimum price point will need to take account of a relatively small patient population, consuming a limited number of doses, which is inherent in the single treatment paradigm. The list price of such a drug will be based, in part, on the value of future cost avoidance. This future-value issue is of great concern to payers. Will the same payer still be on board to accrue the benefits in the context of a transient patient population? This is less of an issue in national systems, where there is only one payer at any given stage of the disease progression.

In the fragmented US healthcare market, the Affordable Care Act was intended to control medical costs, in part by market competition. Individuals can switch insurance plans freely with insurance exchanges and community-based underwriting. The average tenure in an individual plan is around three years. Moreover, the health insurance industry has traditionally based its business model on a one-year underwriting time horizon.

Clearly the business question emerges: how do we value future cost avoidance and health benefits that may accrue to a party other than the original payer?

Medical economists have proposed a variety of fixes for this conundrum: reinsurance; multi-year underwriting; and cost-sharing pools. Upon deeper analysis, some variation on reinsurance appears to be the most manageable. It is a standard practice in other types of insurance, and is transparent to the patients, providers and innovators. In the end, economic success of the next wave of therapeutic innovation depends on the collaboration of, and cooperation among, all stakeholders.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, and an industry consultant with over 25 years of experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Tabletability, Compactability, and Compressibilty: What’s the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement